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To the Editor: Aime and colleagues1 suggest that the Food
and Drug Administration (FDA) guidance on gadolinium-
based contrasting agents should lead to caution in the use of
lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals,
Basingstoke, UK). The basis for their concern is that
gadolinium and lanthanum are similar physiochemically.
Gadolinium salts administered intravenously have known
toxicities and thus chelates are used to limit them.2 These are
administered usually at single intravenous doses of 0.1 mmol/
kg, leading to plasma gadolinium concentrations of up to
2.5 mmol/l (392.5 mg/l) at standard doses2 and 5 mmol/l
(785 mg/l) at double doses used for magnetic resonance
imaging angiography. The chelates are cleared primarily by
renal elimination. Thus, the half-life of gadolinium increases
from 1.96 h in healthy individuals to 5.61 anzd 9.18 h in patients
with chronic kidney disease stages 4 and 5, respectively.3
Prolonged systemic exposure increases the potential for
transmetalation and the release of free gadolinium. It is believed
that this free gadolinium forms insoluble complexes and
deposits in the skin and other organs.4
The exposure paradigms for gadolinium and lanthanum
are completely different. Gram doses of intravenous gadoli-
nium are 100% bioavailable, whereas oral lanthanum
carbonate has a bioavailability of 0.00127%.5 Plasma
lanthanum concentrations following long-term treatment
plateau at nanomolar levels of 2.5–9.7 nmol/l;6 approximately
500,000-fold lower than for gadolinium double dosing.
Furthermore, absorbed lanthanum is highly protein bound
(499.7%),5 resulting in free plasma lanthanum concentra-
tions in the pmol/l range. Rodent toxicity studies demon-
strate that skin concentrations of lanthanum are negligible
(oral gavage or intravenous dosing).7
There are no reports of nephrogenic systemic fibrosis asso-
ciated with lanthanum carbonate either in clinical trials (over
5000 patients) or in post-marketing surveillance (data on file).
The assumption that the risks of gadolinium can be
extrapolated to lanthanum on the basis of proximity in the
periodic table, rather than on pharmacokinetic, toxicologic,
and clinical evidence, is not warranted and scientifically
inappropriate.
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The biodistribution of lanthanum(III) complexes relies on
their speciation (that is, the distribution among chemical
species that provide coordination sites to the lanthanum(III)
ions). Among the huge number of biomolecules, the
speciation of lanthanum (III) complexes is determined by
their relative thermodynamic stabilities.1
The close analogy in the coordination chemistry of
lanthanum and gadolinium trivalent ions allows one to
anticipate that there would be analogies in the bio-
distribution of the two ions in living systems. However,
the administration route (oral or intravenous), the
quantities involved, and the chemical differences of the
forms that reach the blood (as highly thermodynamically
stable chelates in the case of gadolinium or speciated
among different biomolecules in the case of lanthanum
arising from the orally administered carbonate) generate
differences between the two protocols. Attention should be
invoked to consider the complex picture made of a number
of intercorrelated equilibria (that are analogous for the
two ions). On the basis of the tremendous output that
comes from the use of not sufficiently stable gadolinium
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chelates in magnetic resonance imaging, more efforts
should be devoted to characterize the in vivo distribution/
accumulation of lanthanum upon oral administration of
lanthanum carbonate.
The observation of plasma lanthanum concentrations in
blood that plateau at nanomolar values does not guarantee
against its deposition/accumulation outside the blood
circuit. In the absence of a clear understanding of the
ethiology of nephrogenic systemic fibrosis (and, in
particular, of the co-causes that determine the develop-
ment of the disease), it appears definitively not possible to
assume the absence of risks associated to the lanthanum
carbonate treatment.2
It is worth to note that the same concern has been
expressed in the ‘Guidance Document for safe MR practice’
that has been recently published by the American College of
Radiology: ‘There are early data that suggest that elevated
levels of phosphate, iron, zinc or copper or the presence of
Fosrenol (lanthanum carbonate, Shire) might serve as
efficient competitors for the ‘attention’ of the chelate
molecule, so to speak, and increase the concentration of
free gadolinium in the patient, which might therefore
increase the potential of the patient to develop NSF’ (p 13)
and ‘other cations such as lanthanum, now used as
lanthanum carbonate (Fosrenol) for phosphorus binding in
end-stage renal disease patients, could also present similar
transmetallation and free gadolinium concernsy’ (p 15).3
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To the Editor: In their recent article on continuous ambulatory
hemofiltration, Gura et al.1 state, ‘This study describes the first
human use of a wearable hemofiltration device to manage fluid
overload’ and claim, ‘This first-ever human study of a wearable
hemofiltration device indicates that its application as such is
feasible.’ The claims of priority and novelty embedded in these
statements are simply not true. Neff et al.2 in 1988, Shaldon
et al.3 1989, Murisasco et al.4 in 1986, and Takai et al.5 in 1991
have all published clinical trials involving wearable ultrafiltra-
tion devices. None were cited in the article by Gura et al. ‘All
four authors conducted clinical tests on dialysis patients and,
although Gura et al., discuss application to cardiovascular
disease their study group was the same as in earlier
investigations.’ The potential of using isolated ultrafiltration
in diuretic-resistant cardiac failure has also been reported and
was poorly tolerated in advanced cases.6 The published works
by Neff et al.,2 Shaldon et al.,3 Murisasco et al.,4 and Takai
et al.5 are not difficult to find: they will turn up in a simple
PubMed search or even on Google with keywords ‘wearable
ultrafilter’ or ‘ambulatory hemofiltration.’ Also, their content is
highly relevant. Three of the four earlier reports describe
significantly higher fluid removal rates than were reported by
Gura et al.; the third describes clinical evaluation in patients
not for 6 h (Gura et al.) but for 21 days (Shaldon et al.). In this
latter case, the device was custom designed with wide bore
fibers allowing the ambulatory patient to be anticoagulated
with aspirin rather than by heparin. Investigators are certainly
entitled to present their findings in the most favorable light.
However, it is never appropriate to omit readily available earlier
citations, and thereby blur the distinction between contribu-
tions of a pioneering and breakthrough nature and efforts,
which merely represent ongoing evolution. The peer-review
process is supposed to prevent this Plimsoll line from being
crossed, but, in this case, regrettably, it failed to do so.
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We thank Professors Shaldon and Lysaght1 for their
insightful letter. The concept of developing wearable
devices for treating both patients with heart failure and
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